TIRZ / IGF-1 LR3Interpret the evidence
What basal insulin studies tell us about the limits of an add-on result
3 numbered sourcesSource years 2023, 2026
Peptides are short chains of amino acids joined by peptide bonds. Some carry signals that help regulate glucose. Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is a modified insulin-like growth factor protein. A 2026 analysis examined tirzepatide added to basal insulin and shows why an add-on result has to be read with the exact background treatment in view. [1, 2, 3]
Basal insulin supplies background insulin between meals and overnight. The analysis used two trials in adults with type 2 diabetes whose glucose remained above target while receiving basal insulin. One trial compared the addition of tirzepatide with placebo. The other compared it with addition of a rapid-acting insulin. The two comparisons provided different ways to ask what happened when a treatment was added to a common background. [1]
The analysis reported changes in HbA1c and fasting glucose among participants receiving tirzepatide. It also examined clinically significant episodes of low blood sugar. The authors considered whether the frequency of those episodes varied with participants’ starting characteristics, including age and duration of diabetes. Average glucose and episodes of unusually low glucose were recorded as different outcomes. [1]
IGF-1 LR3 was not the background insulin or the added intervention in these trials. Its name refers to a growth-factor analog, which is a different molecule from the insulins in the study. The observed glucose and safety results describe tirzepatide under the tested insulin protocols. They cannot predict the frequency or severity of low glucose with the catalog pair, which would require a comparison that explicitly studies those two ingredients together. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
